Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

I Ubink; HJ Bloemendal; SG Elias; MA Brink; MP Schwartz; YCW Holierhoek; PM Verheijen; AW Boerman; Ron Mathijssen; WWJ de Leng; RA de Weger; WMU van Grevenstein; M Koopman; Martijn Lolkema; O Kranenburg; I Rinkes

doi:10.1186/s12885-017-3264-y

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

I Ubink, HJ Bloemendal, SG Elias, MA Brink, MP Schwartz, YCW Holierhoek, PM Verheijen, AW Boerman, Ron Mathijssen, WWJ de Leng, RA de Weger, WMU van Grevenstein, M Koopman, Martijn Lolkema, O Kranenburg, I Rinkes

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

6 Downloads (Pure)

Original language	Undefined/Unknown
Article number	282
Journal	BMC Cancer
Volume	17
DOIs	https://doi.org/10.1186/s12885-017-3264-y
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12885-017-3264-y

REPUB_99521-OA.pdfFinal published version, 488 KB

http://hdl.handle.net/1765/99521

Cite this

Ubink, I., Bloemendal, HJ., Elias, SG., Brink, MA., Schwartz, MP., Holierhoek, YCW., Verheijen, PM., Boerman, AW., Mathijssen, R., de Leng, WWJ., de Weger, RA., van Grevenstein, WMU., Koopman, M., Lolkema, M., Kranenburg, O., & Rinkes, I. (2017). Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer, 17, Article 282. https://doi.org/10.1186/s12885-017-3264-y

@article{d3b51d499cf24454b03bc57208827881,

title = "Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)",

author = "I Ubink and HJ Bloemendal and SG Elias and MA Brink and MP Schwartz and YCW Holierhoek and PM Verheijen and AW Boerman and Ron Mathijssen and {de Leng}, WWJ and {de Weger}, RA and {van Grevenstein}, WMU and M Koopman and Martijn Lolkema and O Kranenburg and I Rinkes",

year = "2017",

doi = "10.1186/s12885-017-3264-y",

language = "Undefined/Unknown",

volume = "17",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

Ubink, I, Bloemendal, HJ, Elias, SG, Brink, MA, Schwartz, MP, Holierhoek, YCW, Verheijen, PM, Boerman, AW, Mathijssen, R, de Leng, WWJ, de Weger, RA, van Grevenstein, WMU, Koopman, M, Lolkema, M, Kranenburg, O & Rinkes, I 2017, 'Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)', BMC Cancer, vol. 17, 282. https://doi.org/10.1186/s12885-017-3264-y

TY - JOUR

T1 - Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

AU - Ubink, I

AU - Bloemendal, HJ

AU - Elias, SG

AU - Brink, MA

AU - Schwartz, MP

AU - Holierhoek, YCW

AU - Verheijen, PM

AU - Boerman, AW

AU - Mathijssen, Ron

AU - de Leng, WWJ

AU - de Weger, RA

AU - van Grevenstein, WMU

AU - Koopman, M

AU - Lolkema, Martijn

AU - Kranenburg, O

AU - Rinkes, I

PY - 2017

Y1 - 2017

U2 - 10.1186/s12885-017-3264-y

DO - 10.1186/s12885-017-3264-y

M3 - Article

SN - 1471-2407

VL - 17

JO - BMC Cancer

JF - BMC Cancer

M1 - 282

ER -